Viking Therapeutics, Inc.
VKTX
$35.63
$0.160.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 48.39M | 52.36M | 57.52M | 53.39M | 49.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 393.34M | 274.84M | 212.84M | 172.32M | 150.92M |
| Operating Income | -393.34M | -274.84M | -212.84M | -172.32M | -150.92M |
| Income Before Tax | -359.64M | -237.39M | -171.55M | -128.24M | -109.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -359.64 | -237.39 | -171.55 | -128.24 | -109.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -359.64M | -237.39M | -171.55M | -128.24M | -109.96M |
| EBIT | -393.34M | -274.84M | -212.84M | -172.32M | -150.92M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.18 | -2.12 | -1.53 | -1.15 | -1.01 |
| Normalized Basic EPS | -1.99 | -1.32 | -0.96 | -0.72 | -0.63 |
| EPS Diluted | -3.18 | -2.12 | -1.53 | -1.15 | -1.01 |
| Normalized Diluted EPS | -1.99 | -1.32 | -0.96 | -0.72 | -0.63 |
| Average Basic Shares Outstanding | 450.53M | 447.87M | 446.46M | 444.71M | 436.10M |
| Average Diluted Shares Outstanding | 450.53M | 447.87M | 446.46M | 444.71M | 436.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |